KFH - VALLEJO
- Type
- Teaching hospital
- Where
- VALLEJO, CA
- Medicare CCN
- 050073
- Received
- $62,914 in 46 records, 2019 ($3,098 general, $59,815 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 2 | $3,098 |
| 2019 | Research payment | 44 | $59,815 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $39,006 | 2019 |
| Incyte Corporation | 40 | $19,640 | 2019 |
| Olympus America Inc. | 1 | $3,052 | 2019 |
| Endologix LLC | 1 | $1,040 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $128 | 2019 |
| Zimmer Biomet Holdings, Inc. | 1 | $46 | 2019 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 44 | $59,815 |
| Education | 1 | $3,052 |
| Gift | 1 | $46 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $46 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-18 | Incyte Corporation | $800 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-12-18 | Incyte Corporation | $26 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-12-09 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-11-21 | Incyte Corporation | $11,775 | Research payment | Cash or cash equivalent | A Single Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid Refractor | 2019 | |
| 2019-10-17 | Incyte Corporation | $1,892 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-10-10 | E.R. Squibb & Sons, L.L.C. | $28,706 | Research payment | Cash or cash equivalent | NASH cohort algorithm and validation using a hospital based record system | 2019 | |
| 2019-10-10 | Endologix LLC | $1,040 | Research payment | Cash or cash equivalent | AFX Device, Cardiology/Vascular Diseases | LEOPARD | 2019 |
| 2019-08-08 | Incyte Corporation | $754 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $127 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $81 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $62 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $35 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $31 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $25 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $23 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $5 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $4 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-08-08 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Study of INCMGA00012 in Participants With Selected Solid Tumors POD1UM-203 | 2019 | |
| 2019-07-10 | Incyte Corporation | $22 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-07-10 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-07-10 | Incyte Corporation | $11 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-06-01 | Olympus America Inc. | $3,052 | Education | In-kind items and services | Endocuff Devices Device, GI & Respiratory Products | 2019 | |
| 2019-05-08 | E.R. Squibb & Sons, L.L.C. | $10,300 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Neoadjuvant NSCLC nivo chemo | 2019 |
| 2019-05-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-05-08 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-03-12 | Incyte Corporation | $2,250 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cel | 2019 | |
| 2019-03-12 | Incyte Corporation | $1,200 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cel | 2019 | |
| 2019-03-12 | Incyte Corporation | $200 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cel | 2019 | |
| 2019-03-08 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-28 | Incyte Corporation | $22 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-28 | Incyte Corporation | $20 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-28 | Incyte Corporation | $15 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-28 | Incyte Corporation | $9 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-28 | Incyte Corporation | $0 | Research payment | Cash or cash equivalent | A Double Blind, Double Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagreli | 2019 | |
| 2019-01-03 | Merck Sharp & Dohme LLC | $128 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Vallejo, CA, county Solano County, CA, state California; placed by its city name.
| Measure | Place (city or town) Vallejo, CA | County Solano County, CA | State California |
|---|---|---|---|
| Population B01003 | 124,268 | 451,918 | 39,287,377 |
| Population, 2020 census P1 | 126,090 | 453,491 | 39,538,223 |
| Median age B01002 | 40.6 | 39.2 | 37.9 |
| Under 18 B01001 | 20.0% | 21.9% | 22.0% |
| 65 and over B01001 | 17.9% | 17.4% | 15.7% |
| Households B11001 | 44,798 | 157,512 | 13,548,091 |
| Foreign born B05002 | 28.7% | 20.8% | 27.0% |
| Median household income B19013 | $90,171 | $100,401 | $99,122 |
| Median family income B19113 | $103,860 | $116,065 | $113,346 |
| Per capita income B19301 | $42,240 | $45,127 | $49,513 |
| Poverty rate B17001 | 12.2% | 10.0% | 12.0% |
| Unemployment rate B23025 | 7.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 63,631 | 220,729 | 20,068,466 |
| Mean commute (minutes) B08013 | 34.2 | 31.0 | 28.7 |
| Bachelor's degree or higher B15003 | 28.8% | 28.8% | 37.1% |
| Housing units B25001 | 47,084 | 164,693 | 14,644,735 |
| Owner-occupied B25003 | 57.4% | 63.0% | 55.9% |
| Renters B25003 | 42.6% | 37.0% | 44.1% |
| Median home value B25077 | $589,500 | $617,700 | $734,700 |
| Median gross rent B25064 | $2,073 | $2,163 | $2,036 |
| White, not Hispanic B03002 | 20.5% | 33.2% | 33.8% |
| Black B03002 | 16.9% | 12.3% | 5.2% |
| Hispanic or Latino B03002 | 29.8% | 29.6% | 40.2% |
| Asian B03002 | 22.7% | 15.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Vallejo, CA.
Comments